Niraparib (Zejula®) is indicated as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
|NCPE Assessment Process||Ongoing|
|Rapid review commissioned||22/02/2021|
|Rapid review completed||26/03/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of niraparib (Zejula®) compared with the current standard of care.|